Option chain shows key data for Cyclacel Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock, Option Chain

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

xr:d:DAFfORZ4lNo:2,j:2185570849,t:23040509

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BJDX

BURU

CLDI

CYCC

DBGI

EFSH

ELAB

HROW

IBTA

MTNB

QBTS

QUBT

SMCI

SVMH

TSHA

XTIA

ZCAR

ZETA

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Nvidia, Palantir, Clover Health, Joby Aviation, Tesla: Why These 5 Stocks Are On Investors' Radars Today

DAVE

GRPN

HNRG

IAUX

KAPA

MAPS

MULN

MVST

NMHI

Next Technology Holding Inc. - Ordinary Shares

NXTT

RKLB

SAVE

SIDU

SYRS

Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

Biotech

Earnings

Mid Cap

Penny Stocks

Technicals

Analyst Ratings

General

A downtrend has been apparent in Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) lately. While the stock has lost 13.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session.

Cyclacel Pharmaceuticals May Find a Bottom Soon, Here&#39;s Why You Should Buy the Stock Now

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder.
The Company's Board of Directors is reviewing a range of appropriate strategies to realize value from its assets. The Board has directed management to reduce operating costs while such alternatives are being explored. There can be no assurance that the exploration of strategic alternatives will result in any agreement or transaction, or as to the timing of any such agreement or transaction. Further, there can be no assurance that the Company will be able to reach an agreement, or consummate a transaction, with Mr. Lazar or receive the required consent of an existing securityholder to any such transaction.
As previously disclosed, the Company does not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. In the event that the Company is not able to enter into a strategic transaction and/or secure additional funding, it may be forced to cease all business operations. In such event, the Company's stockholders may lose a part or all of their investment in the Company.

CYCCP

Cyclacel Pharmaceuticals Announces Its Exploration Of Potential Strategic Alternatives On An Expedited Basis In Order To Preserve The Company's Cash, Including A Potential Transaction With Investor David Lazar Of Activist Investing, LLC

Shares of DLocal Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/quote/DLO/earnings">third-quarter revenue results</a>.
DLocal reported quarterly earnings of 9 cents per share which missed the analyst consensus estimate of 11 cents per share. The company reported quarterly sales of $185.774 million which beat the analyst consensus estimate of $181.463 million.
DLocal shares jumped 18.3% to $10.70 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 91.1% to $0.0472 in pre-market trading after surging 32% on Wednesday.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) rose 40% to $0.0339 in pre-market trading.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) gained 35.7% to $0.0777 in pre-market trading after gaining 18% on Wednesday.</li>
<li>Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) gained 28.7% to $0.5335 in pre-market trading.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) gained 26.9% to $8.25 in pre-market trading after the company reported second-quarter results.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) climbed 25.8% to $3.34 in pre-market trading after jumping more than 92% on Wednesday.</li>
<li>Zeta Global Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) gained 20.5% to $21.40 in pre-market trading. Zeta Global increased its share repurchase program with $100 million buyback authorization through 2026.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) gained 17.7% to $0.5301 in pre-market trading after dipping 58% on Wednesday.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) gained 14.6% to $2.04 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Calidi Biotherapeutics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NYSE">CLDI</a>) shares tumbled 27% to $2.47 in pre-market trading after the company announced a proposed public offering.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) shares fell 26.5% to $0.1329 in pre-market trading after jumping over 40% on Wednesday.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) declined 25.8% to $38.45 in pre-market trading after the company reported worse-than-expected third-quarter sales results.</li>
<li>Ibotta, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) shares fell 22.9% to $57.75 in pre-market trading after the company reported quarterly results.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) fell 18.7% to $0.3658 in pre-market trading after gaining around 10% on Wednesday.</li>
<li>Bluejay Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) dipped 18.3% to $0.0850 in pre-market trading after the company reported a 1-for-50 reverse stock split.</li>
<li>Matinas BioPharma Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#NYSE">MTNB</a>) shares dipped 15.9% to $0.5969 in pre-market trading after falling around 5% on Wednesday.</li>
<li>ESS Tech, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) fell 13.8% to $7.68 in pre-market trading following third-quarter results.</li>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) fell 10.8% to $1.9700 in pre-market trading following third-quarter results.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 10.1% to $18.27 in today's pre-market trading. Super Micro Computer shares fell 6% on Wednesday after the company announced it was unable to file its quarterly report for the period ending Sept. 30 in a timely manner.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41962884/us-stocks-settle-mixed-following-inflation-data-investor-sentiment-improves-but-fear-index-remains-in-greed-zone">US Stocks Settle Mixed Following Inflation Data: Investor Sentiment Improves, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-279157).
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.

Offerings

Cyclacel Pharmaceuticals Announces Exercise Of Warrants For $2.1M, Has Entered Into A Definitive Agreement For The Exercise Of Certain Existing Warrants To Purchase An Aggregate Of 4,968,945 Shares Of Its Common Stock Having An Original Exercise Price Of $1.36 Per Share, Originally Issued In May 2024, At A Reduced Exercise Price Of $0.415 Per Share

WIIM

Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

Shares of Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/general/space/24/11/41922070/rocket-lab-q3-earnings-revenue-beat-eps-beat-continued-strong-demand-growth-multi-launch-agreement-air-force-award-and-more">third-quarter financial results</a>.
The company also announced a multi-launch agreement with a confidential commercial satellite constellation operator and was awarded a federal defense contract worth up to $8 million.
Rocket Lab USA shares jumped 28.7% to $18.86 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) gained 79.5% to $0.3244 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 62.6% to $0.6682 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) rose 56% to $0.1337 in pre-market trading. Nature&#8217;s Miracle announced the closing of $3.0 million public offering.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) gained 37.3% to $86.21 in pre-market trading after the company reported a profit for the third quarter.</li>
<li>Paymentus Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) climbed 27.8% to $34.02 in pre-market trading following strong earnings and guidance.</li>
<li>Kairos Pharma, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#NYSE">KAPA</a>) gained 26.1% to $2.59 in pre-market trading after jumping 51% on Tuesday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) gained 20.1% to $3.58 in pre-market trading. Mullen Automotive shares jumped 74% on Tuesday after the company announced its Class 1 EV cargo van is listed for vehicle rental on Turo.</li>
<li>WM Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) rose 19.9% to $0.8585 in pre-market trading after the company reported better-than-expected third-quarter revenue results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Hallador Energy Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) gained 14.2% to $11.93 in pre-market trading following third-quarter earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares tumbled 81% to $0.5199 in pre-market trading after the company announced its SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint and has discontinued the study.</li>
<li>Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) shares fell 62.4% to $1.21 in pre-market trading after the company failed to file its earnings for the quarter ended September 2024. The discount airline in a filing late Tuesday, said that it is in talks with its creditors to carve out a restructuring plan which could lead to the cancellation of its equity shares.</li>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) declined 44.8% to $1.24 in pre-market trading after the company priced its $7 million public offering of 5.6 million common shares at $1.25 each.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) shares fell 43% to $0.6100 in pre-market trading after dipping 46% on Tuesday.</li>
<li>Vroom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRM#NASDAQ">VRM</a>) fell 32.8% to $5.96 in pre-market trading following third-quarter results.</li>
<li>Nano Labs Ltd  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) dipped 23.3% to $5.90 in pre-market trading after jumping 134% on Tuesday. The company recently said it will start accepting payments in Bitcoin.</li>
<li>i-80 Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAUX#NYSE">IAUX</a>) fell 21.3% to $0.7150 in pre-market trading after posting third-quarter results.</li>
<li>Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares dipped 21.4% to $8.90 in pre-market trading after reporting third-quarter results.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) fell 21.2% to $1.60 in today's pre-market trading after jumping over 76% on Tuesday.</li>
<li>ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) fell 13.8% to $11.28 in pre-market trading following third-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41929909/dow-sp-decline-ahead-of-key-inflation-data-tesla-trump-media-slides-fear-index-remains-in-greed-zone">Dow, S&amp;P Decline Ahead Of Key Inflation Data, Tesla, Trump Media Slides: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.56) by 67.86 percent. The company reported quarterly sales of $10.000 thousand which beat the analyst consensus estimate of $5.000 thousand by 100.00 percent.

Earnings Beats

Cyclacel Pharmaceuticals Q3 2024 GAAP EPS $(0.18) Beats $(0.56) Estimate, Sales $10.000K Beat $5.000K Estimate

Cyclacel Pharmaceuticals Requests SEC For Withdrawal Of Registration, Due To Decision Not To Pursue Public Offering

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 124.5% to $1.3 during Monday's regular session. The market value of their outstanding shares is at $7.3 million. </li>
<li>Monte Rosa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLUE#NASDAQ">GLUE</a>) shares increased by 117.99% to $10.66. The market value of their outstanding shares is at $654.2 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 69.81% to $9.0. The company's market cap stands at $6.6 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 44.51% to $6.72. The company's market cap stands at $87.4 million. </li>
<li>EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) shares moved upwards by 36.31% to $12.95. The market value of their outstanding shares is at $693.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares increased by 30.8% to $2.59. The company's market cap stands at $6.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares fell 18.3% to $4.91 during Monday's regular session. The company's market cap stands at $25.5 million. </li>
<li>Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock decreased by 15.92% to $26.63. The market value of their outstanding shares is at $24.8 billion. The company's, Q3 earnings came out today. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 14.11% to $2.62. The company's market cap stands at $447.0 million. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares decreased by 13.83% to $1.62. The market value of their outstanding shares is at $36.7 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 12.85% to $0.73. The company's market cap stands at $1.4 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares declined by 12.73% to $1.44. The market value of their outstanding shares is at $7.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVOK

EYPT

GLUE

GNPX

HCTI

ITRM

SONN

TVGN

12 Health Care Stocks Moving In Monday's Intraday Session

Cyclacel Pharmaceuticals Receives Extension From Nasdaq To Regain Compliance With Equity Standard Rule Until December 24, 2024

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares increased by 27.4% to $3.16 during Thursday's pre-market session. The company's market cap stands at $539.2 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares moved upwards by 24.11% to $0.17. The market value of their outstanding shares is at $5.6 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 21.51% to $0.83. The market value of their outstanding shares is at $79.4 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) stock moved upwards by 19.65% to $2.07. The company's market cap stands at $101.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) shares increased by 17.24% to $0.2. The market value of their outstanding shares is at $5.5 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock rose 14.78% to $2.95. The company's market cap stands at $23.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares declined by 16.8% to $0.11 during Thursday's pre-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock decreased by 13.59% to $2.29. The company's market cap stands at $5.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock declined by 13.56% to $0.35. The market value of their outstanding shares is at $4.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 12.27% to $0.93. The company's market cap stands at $1.8 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares declined by 12.13% to $0.29. The market value of their outstanding shares is at $5.2 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock decreased by 9.18% to $0.52. The company's market cap stands at $3.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTR

BIVI

CNSP

DBVT

ENSC

MNOV

NDRA

Qualigen Therapeutics, Inc. - Common Stock

QLGN

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock rose 28.6% to $3.19 during Thursday's pre-market session. The company's market cap stands at $544.3 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares moved upwards by 24.04% to $0.17. The company's market cap stands at $5.6 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 22.17% to $0.83. The company's market cap stands at $79.9 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares moved upwards by 19.65% to $2.07. The company's market cap stands at $101.5 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock rose 14.82% to $0.2. The company's market cap stands at $5.3 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 14.78% to $2.95. The market value of their outstanding shares is at $23.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares declined by 16.9% to $0.11 during Thursday's pre-market session. The company's market cap stands at $10.8 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares decreased by 13.97% to $2.28. The market value of their outstanding shares is at $5.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock fell 13.24% to $0.35. The market value of their outstanding shares is at $4.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 12.27% to $0.93. The market value of their outstanding shares is at $1.8 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares decreased by 12.13% to $0.29. The market value of their outstanding shares is at $5.2 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock decreased by 9.18% to $0.52. The company's market cap stands at $3.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 92.5% to $0.3 during Wednesday's regular session. The company's market cap stands at $9.6 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) stock rose 63.89% to $2.75. The market value of their outstanding shares is at $11.9 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 59.31% to $2.56. The company's market cap stands at $437.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock rose 42.54% to $1.0. The company's market cap stands at $95.9 million. </li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) shares increased by 36.35% to $1.65. The company's market cap stands at $343.5 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 22.47% to $4.12. The market value of their outstanding shares is at $32.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares declined by 66.1% to $4.93 during Wednesday's regular session. The market value of their outstanding shares is at $132.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 27.74% to $0.33. The market value of their outstanding shares is at $4.4 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 26.44% to $0.4. The company's market cap stands at $5.4 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares fell 25.26% to $0.72. The market value of their outstanding shares is at $2.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 25.18% to $1.07. The company's market cap stands at $2.1 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock fell 23.73% to $1.8. The market value of their outstanding shares is at $3.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANRO

ALPS ETF Trusthen & Steers Global Realty Majors ETF

NUWE

SGMO

SLXN

VRAX

12 Health Care Stocks Moving In Wednesday's Intraday Session

Cyclacel Pharmaceuticals shares are trading higher after the company announced it reported clinical data from its ongoing Phase 2 study of oral Fadraciclib at the 2024 EORTC-NCI-AACR symposium.

Events

Cyclacel Pharmaceuticals Reports Clinical Data From Ongoing, Phase 2 Study Of Oral Fadraciclib At 2024 EORTC-NCI-AACR Symposium

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock moved upwards by 143.7% to $0.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $12.2 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock increased by 62.87% to $1.14. The market value of their outstanding shares is at $109.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 46.15% to $2.09. The company's market cap stands at $4.1 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares moved upwards by 34.59% to $0.38. The market value of their outstanding shares is at $14.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) shares moved upwards by 25.49% to $3.2. The market value of their outstanding shares is at $61.0 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares increased by 19.34% to $4.01. The company's market cap stands at $32.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) stock decreased by 62.3% to $5.48 during Wednesday's pre-market session. The company's market cap stands at $147.7 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 18.58% to $0.44. The market value of their outstanding shares is at $6.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock declined by 14.49% to $3.07. The company's market cap stands at $7.9 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) stock decreased by 14.46% to $2.13. The company's market cap stands at $52.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock fell 12.7% to $0.31. The market value of their outstanding shares is at $4.1 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock decreased by 11.51% to $4.0. The company's market cap stands at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

CELZ

MBIO

TELA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 143.7% to $0.38 during Wednesday's pre-market session. The company's market cap stands at $12.2 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) stock moved upwards by 62.87% to $1.14. The company's market cap stands at $109.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 46.15% to $2.09. The market value of their outstanding shares is at $4.1 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares rose 34.59% to $0.38. The company's market cap stands at $14.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock rose 25.49% to $3.2. The market value of their outstanding shares is at $61.0 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 19.34% to $4.01. The market value of their outstanding shares is at $32.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Alto Neuroscience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>) shares decreased by 62.3% to $5.48 during Wednesday's pre-market session. The market value of their outstanding shares is at $147.7 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 18.58% to $0.44. The company's market cap stands at $6.0 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock decreased by 14.49% to $3.07. The company's market cap stands at $7.9 million. </li>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares fell 14.46% to $2.13. The company's market cap stands at $52.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 12.7% to $0.31. The company's market cap stands at $4.1 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock declined by 11.51% to $4.0. The market value of their outstanding shares is at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) stock rose 16.6% to $72.43 during Monday's after-market session. The company's market cap stands at $2.2 billion. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares increased by 13.63% to $0.38. The company's market cap stands at $2.8 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares moved upwards by 5.87% to $1.26. The market value of their outstanding shares is at $89.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock rose 5.16% to $1.39. The company's market cap stands at $2.7 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares rose 5.12% to $0.2. The market value of their outstanding shares is at $21.7 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares increased by 4.99% to $0.84. The market value of their outstanding shares is at $119.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares declined by 20.5% to $0.62 during Monday's after-market session. The market value of their outstanding shares is at $15.5 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares fell 13.27% to $0.41. The company's market cap stands at $29.8 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) stock decreased by 12.17% to $310.0. The company's market cap stands at $9.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares declined by 9.28% to $1.37. The market value of their outstanding shares is at $3.5 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 8.56% to $0.64. The company's market cap stands at $2.8 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock declined by 7.48% to $0.99. The company's market cap stands at $3.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTOR

INAB

IRTC

MEDP

PTIX

SNSE

WINT

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares increased by 142.8% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares moved upwards by 49.28% to $2.06. The market value of their outstanding shares is at $351.5 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock rose 39.74% to $0.92. The company's market cap stands at $3.6 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) stock rose 30.56% to $0.63. The company's market cap stands at $13.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock rose 30.46% to $1.32. The market value of their outstanding shares is at $2.6 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock rose 27.86% to $1.15. The market value of their outstanding shares is at $29.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 31.9% to $0.48 during Friday's regular session. The company's market cap stands at $16.8 million. </li>
<li>Orgenesis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGS#NASDAQ">ORGS</a>) shares declined by 28.05% to $2.33. The market value of their outstanding shares is at $11.1 million. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock decreased by 16.1% to $0.78. The market value of their outstanding shares is at $5.1 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) stock declined by 12.7% to $2.27. The company's market cap stands at $17.8 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares decreased by 9.04% to $0.7. The market value of their outstanding shares is at $4.0 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 8.84% to $1.96. The company's market cap stands at $7.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFRG

CHRO

CMAX

CTCX

MHUA

MTEM

NKGN

ORGS

QNRX

VTAK

12 Health Care Stocks Moving In Friday's Intraday Session

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, ", Cyclacel", or the ", Company", )))), a biopharmaceutical company developing innovative cancer medicines, today announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib as a single agent will be presented as a poster at the 2024 AACR-NCI-EORTC 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), to be held in Barcelona, Spain (October 23-25, 2024). The patients were enrolled in the biomarker-enriched, Cohort 8 of the proof of concept study and were preselected for CDKN2A and/or CDKN2B abnormalities.
Details of the presentation are listed below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Title:</td>
<td><a href="https://cm.eortc.org/cmPortal/Searchable/ena2024/config/Normal#!sessiondetails/0000110740_0">Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations</a></td>
</tr>
<tr>
<td>Abstract Number:</td>
<td>59</td>
</tr>
<tr>
<td>Session:</td>
<td>Molecular Targeted Agents</td>
</tr>
<tr>
<td>Date/Time:</td>
<td>12:00 p.m. – 7:00 p.m. CEST on Wednesday, October 23, 2024</td>
</tr>
</tbody>
</table>
</figure>

Cyclacel Pharmaceuticals To Present New Clinical Data From Phase 2 Study Of Oral Fadraciclib At The 2024 EORTC-NCI-AACR Symposium

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Cyclacel Pharmaceuticals (CYCC) announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Pha...

Cyclacel reports clinical data from Phase 2 study of oral fadraciclib

Roth MKM downgraded Cyclacel Pharmaceuticals (CYCC) to Neutral from Buy. Published first on TheFly – the ultimate source for real-time, market-movi...

Cyclacel Pharmaceuticals downgraded to Neutral from Buy at Roth MKM

Roth MKM analyst Jonathan Aschoff downgraded Cyclacel Pharmaceuticals (CYCC) to Neutral from Buy with a price target of $1, down from $11. The stoc...

Roth MKM downgrades Cyclacel to Neutral after 'not encouraging' data

Cyclacel Pharmaceuticals (CYCC) received a written notice from The Nasdaq Stock Market granting the Company an extension until December 24, 2024, t...

Cyclacel Pharmaceuticals granted extension for regain Nasdaq compliance

Cyclacel Pharmaceuticals GAAP EPS of -$0.18 beats by $0.36, revenue of $0.01M in-line

Cyclacel Pharmaceuticals ( ($CYCC) ) has released its Q3 earnings. Here is a breakdown of the information Cyclacel Pharmaceuticals presented to its...

Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results

AGEN

AKBA

ALLK

AXSM

CRMD

FOLD

HRTX

IMUX

MCRB

ONCT

RIGL

SNDX

SWTX

TEVA

XFOR

Health Care

Press Releases

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cardiol Therapeutics' (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Financing

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

Comments

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (CYCC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga